Effect of fenofibrate on serum nitric oxide levels in patients with hypertriglyceridemia

dc.contributor.authorEsenboga, Kerim.
dc.contributor.authorÇiçek, Ömer Faruk.
dc.contributor.authorOktay, Ahmet Afşin.
dc.contributor.authorAyral, Pelin Aribal.
dc.contributor.authorGürlek, Adalet.
dc.date.accessioned2020-03-26T20:13:37Z
dc.date.available2020-03-26T20:13:37Z
dc.date.issued2019
dc.departmentSelçuk Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground. Fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPAR alpha) agonist, is used to treat patients with hypercholesterolemia and hypertriglyceridemia in order to reduce the risk of development of the atherosclerotic cardiovascular disease. However, it exerts pleiotropic effects beyond correcting atherogenic dyslipidemia to treat hypercholesterolemia. Objectives. The aim of this study was to investigate the potential effects of fenofibrate on endothelial function by analyzing the serum nitric oxide (NO) levels in patients with hypertriglyceridemia. Material and methods. Lipid profiles and serum NO levels were assessed in 56 healthy adults aged 29 to 84 years, before and after 12 weeks of fenofibrate (250 mg/d; n = 30) or placebo (n = 26). Appropriate dietary suggestions for hypertriglyceridemia were made for all patients. This study was randomized, double-blind and placebo-controlled in design. Results. Total cholesterol, low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and triglyceride levels significantly decreased; high-density lipoprotein (HDL) and NO levels significantly increased after 12 weeks of fenofibrate therapy. We observed a statistically significant correlation between the increase in serum NO levels and decrease in serum triglyceride levels (r = -0.42, p = 0.02) in the fenofibrate group. Conclusions. The positive effect of short-term fenofibrate treatments on vascular endothelial functions in patients with hypertriglyceridemia has been demonstrated by increasing the serum NO levels. Agents such as fenofibrate targeting PPAR alpha-associated signaling pathways show promise as an alternative treatment of vascular dysfunction related to advanced age and hyperlipidemia.en_US
dc.description.sponsorshipAssociation of Turkish Clinical Vascular Biologyen_US
dc.description.sponsorshipAssociation of Turkish Clinical Vascular Biologyen_US
dc.identifier.citationEsenboga, K., Çiçek, Ö. F., Oktay, A. A., Ayral, P. A., Gürlek, A. (2019). Effect of Fenofibrate on Serum Nitric Oxide Levels in Patients with Hypertriglyceridemia. Advances in Clinical and Experimental Medicine, 28(7), 931-936.
dc.identifier.doi10.17219/acem/94161en_US
dc.identifier.endpage956en_US
dc.identifier.issn1899-5276en_US
dc.identifier.issue7en_US
dc.identifier.pmid31237119en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage951en_US
dc.identifier.urihttps://dx.doi.org/10.17219/acem/94161
dc.identifier.urihttps://hdl.handle.net/20.500.12395/37729
dc.identifier.volume28en_US
dc.identifier.wosWOS:000478731100013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÇiçek, Ömer Faruk.
dc.language.isoenen_US
dc.publisherWROCLAW MEDICAL UNIVen_US
dc.relation.ispartofADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectfibrateen_US
dc.subjecthypertriglyceridemiaen_US
dc.subjectnitric oxideen_US
dc.titleEffect of fenofibrate on serum nitric oxide levels in patients with hypertriglyceridemiaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Kerim ESENBOGA.pdf
Boyut:
291.33 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access